{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T05:24:44Z","timestamp":1765430684313,"version":"3.46.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To develop and validate a nomogram for predicting the risk of multidrug-resistant organisms (MDROs) infection in diabetic foot ulcer (DFU) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>701 DFU patients were divided into training (491 cases) and validation (210 cases) sets (7:3 ratio). Multivariate logistic regression analysis was performed to identify the independent risk factors for MDRO infection in DFU patients. Two nomogram prediction models were developed based on the independent risk factors. The predictive efficacy of the prediction models was evaluated using the receiver operating characteristic (ROC) curve and calibration curve analysis. The decision curve analysis (DCA) was performed to evaluate the prediction model\u2019s performance during clinical application.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Multivariate logistic regression analysis identified previous antibiotic therapy, surgical therapy, ulcer size&amp;gt;4cm\n                      <jats:sup>2<\/jats:sup>\n                      , and CRP as independent risk factors. Two models were developed and validated based on the analysis. Model 1 included previous antibiotic therapy, surgical therapy, and ulcer size&amp;gt;4cm\n                      <jats:sup>2<\/jats:sup>\n                      . Model 2 added a further laboratory indicator to Model 1, such as CRP. In the training set, the AUC of the nomogram for Model 1and Model 2 was 0.763(95% CI 0.711-0.815) and 0.789 (95% CI 0.740-0.838), respectively, and 0.837 (95% CI 0.744-0.900) and 0.845 (95% CI 0.785-0.905) in the validation set. The Youden indexes for Models 1and 2 were 0.416 and 0.470 in the training set and 0.558 and 0.588 in the validation set, respectively. Notably, Model 2 showed higher sensitivity and specificity. The calibration plot and Hosmer\u2013Lemeshow test for Model 1 and Model 2 indicated that the predicted probability had good consistency with the actual probability in both the training set (P = 0.689 for Model 1 and P = 0.139 for Model 2) and validation set (P = 0.607 for Model 1and P = 0.635 for Model 2). The DCA curve indicated that the models had good clinical utility. All models performed well for both discrimination and calibration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study developed two nomogram models for predicting MDRO infection risk in DFU patients. Model 2, with superior predictive performance, enables early identification of high-risk patients. These models facilitate targeted interventions, potentially reducing MDRO complications and healthcare burdens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1609128","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T05:19:43Z","timestamp":1765430383000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of a risk prediction model for multidrug-resistant organisms infection in diabetic foot ulcer patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Jinghang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bai","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baocheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9(Th) edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1086\/511036","article-title":"Validation of the infectious diseases society of america\u2019s diabetic foot infection classification system","volume":"44","author":"Lavery","year":"2007","journal-title":"Clin Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-3402462","article-title":"Diabetic foot. Part 1: ulcers and infections","volume":"55","author":"Ferreira","year":"2020","journal-title":"Rev Bras Ortop (Sao Paulo)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2176","article-title":"Burden of diabetic foot ulcers for medicare and private insurers","volume":"37","author":"Rice","year":"2014","journal-title":"Diabetes Care"},{"key":"B5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/2042018817744513","article-title":"Financial burden of diabetic foot ulcers to world: A progressive topic to discuss always","volume":"9","author":"Raghav","year":"2018","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1405301","article-title":"Incidence and risk factors for amputation in chinese patients with diabetic foot ulcers: A systematic review and meta-analysis","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.10.1799","article-title":"Functional status of persons with diabetes-related lower-extremity amputations","volume":"24","author":"Peters","year":"2001","journal-title":"Diabetes Care"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.3390\/jcm10091948","article-title":"The influence of multidrug-resistant bacteria on clinical outcomes of diabetic foot ulcers: A systematic review","volume":"10","author":"Matta-Guti\u00e9rrez","year":"2021","journal-title":"J Clin Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/idr.S359157","article-title":"Risk factors for multidrug-resistant organisms infection in diabetic foot ulcer","volume":"15","author":"Liu","year":"2022","journal-title":"Infect Drug Resist"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2019.10.009","article-title":"Assessment of the risk factors of multidrug-resistant organism infection in adults with type 1 or type 2 diabetes and diabetic foot ulcer","volume":"44","author":"Dai","year":"2020","journal-title":"Can J Diabetes"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11274-024-04209-2","article-title":"Identifying multidrug-resistant organisms in diabetic foot ulcers: A study of risk factors and antimicrobial resistance genes","volume":"41","author":"Saleem","year":"2024","journal-title":"World J Microbiol Biotechnol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/1199885","article-title":"Development and validation of a risk prediction model for foot ulcers in diabetic patients","volume":"2023","author":"Lv","year":"2023","journal-title":"J Diabetes Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.890057","article-title":"Nomogram prediction for the risk of diabetic foot in patients with type 2 diabetes mellitus","volume":"13","author":"Wang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e01864-19","DOI":"10.1128\/jcm.01864-19","article-title":"The clinical and laboratory standards institute subcommittee on antimicrobial susceptibility testing: background, organization, functions, and processes","volume":"58","author":"Weinstein","year":"2020","journal-title":"J Clin Microbiol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e3273","DOI":"10.1002\/dmrr.3273","article-title":"Guidelines on the classification of diabetic foot ulcers (Iwgdf 2019)","author":"Monteiro-Soares","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis346","article-title":"2012 Infectious diseases society of america clinical practice guideline for the diagnosis and treatment of diabetic foot infections","volume":"54","author":"Lipsky","year":"2012","journal-title":"Clin Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e3687","DOI":"10.1002\/dmrr.3687","article-title":"Iwgdf\/idsa guidelines on the diagnosis and treatment of diabetes-related foot infections (Iwgdf\/idsa 2023)","volume":"40","author":"Senneville","year":"2024","journal-title":"Diabetes Metab Res Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e3280","DOI":"10.1002\/dmrr.3280","article-title":"Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (Iwgdf 2019 update)","author":"Lipsky","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0200","article-title":"Long-term prognosis of diabetic foot patients and their limbs: amputation and death over the course of a decade","volume":"35","author":"Morbach","year":"2012","journal-title":"Diabetes Care"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.881659","article-title":"Microbial infection and antibiotic susceptibility of diabetic foot ulcer in China: literature review","volume":"13","author":"Du","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa161","article-title":"The impact of multidrug-resistant organisms on outcomes in patients with diabetic foot infections","volume":"7","author":"Henig","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e14864","DOI":"10.1111\/iwj.14864","article-title":"Prevalence of multidrug-resistant bacterial infections in diabetic foot ulcers: A meta-analysis","volume":"21","author":"Yang","year":"2024","journal-title":"Int Wound J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2018.02.013","article-title":"Influence of multidrug resistant organisms on the outcome of diabetic foot infection","volume":"70","author":"Saltoglu","year":"2018","journal-title":"Int J Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtv.2022.05.001","article-title":"C-reactive protein and diabetic foot ulcer infections: A meta-analysis","volume":"31","author":"Zhang","year":"2022","journal-title":"J Tissue Viability"},{"key":"B26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13756-020-00726-5","article-title":"Predicting the occurrence of multidrug-resistant organism colonization or infection in icu patients: development and validation of a novel multivariate prediction model","volume":"9","author":"Wang","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S287852","article-title":"Nomogram model for predicting the risk of multidrug-resistant bacteria infection in diabetic foot patients","volume":"14","author":"Ma","year":"2021","journal-title":"Infect Drug Resist"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1609128\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T05:19:44Z","timestamp":1765430384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1609128\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":27,"alternative-id":["10.3389\/fendo.2025.1609128"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1609128","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"article-number":"1609128"}}